Dr. Daniel Latham, Novartis - PFS18 Qepler Conferences & Summits

Dr. Daniel Latham

Head – Device Development & LCM,
Device Development & Commercialisation

Novartis,
Basel, Switzerland
Novartis is a global healthcare company

Daniel Latham is the Head of Device Development & LCM, where he leads an organisation of around 120 associates responsible for the development and life cycle management of delivery systems of drug/device combinations for both new biologic entities, biosimilars, and new chemical entities.

Over the past 11 years at Novartis, he has overseen significant device and primary packaging developments and launches and has significantly supported the growth of device development and drug/device interaction within the organisation.

Prior to Novartis, he worked in a variety of roles in consumer health¬care, focusing on the development of OTC medicines, transdermal patches, and medical devices.

He has a Ph.D. in controlled drug delivery from Queen Mary, Uni¬versity of London and a bachelor’s degree and master’s degrees in engineering from the University of Sheffield.

Related Sessions:

DRUG/DEVICE COMBINATION
PRODUCTS SUMMIT 2018

  • 4-December-2018
  • Berlin, DE
  • Pharma
Day 2: Wednesday 05, December 2018
BLOCK: INTEGRATING DESIGN CONTROL AND HUMAN FACTORS.
CASE STUDY: Using the delivery system concept to streamline drug/device combination approval in EU in accordance with MDR and article 117 requirements.
  • Delivery system concept in pharma and managing future complexity
  • Delivery system platforms and set up
  • Strategies for streamlining approval of drug/device combinations in EU with respect to introduction of MDR and article 117
View Details

Pre-Filled Syringes
Summit 2018

  • 31-May-2018
  • Berlin, DE
  • Pharma
Day 1: Thursday 31, May 2018
BLOCK: DEVICES MEET NEXT GENERATION FORMULATIONS.
CASE STUDY: Developing delivery systems comprising pre-filled syringes and injection devices.
  • Combination products and delivery systems – reducing development risk.
  • Importance of understanding the design space of a delivery system.
  • Considerations for setting up platforms for delivery systems.
View Details